Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders

Louise De Swart, MD, Jan C.M. Hendriks, Lisa Van der Vorm, Ioav Z. Cabantchik, PhD, Patricia J. Evans, PhD, Eldad A. Hod, MD, Gary M. Brittenham, MD, Yael Furman, Mirian C.H. Janssen, MD, Bart J Biemond, MD, Marius A. MacKenzie, MD PhD, Vera E.J.M. Mattijssen, MD, Raffaella Origa, MD, Renzo Galanello, MD, Robert C. Hider, Dorine W. Swinkels, MD PhD

Blood (2014) 124 (21): 4033.

https://doi.org/10.1182/blood.V124.21.4033.4033

Published: 2014

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart Catheterization

Giorgio Derchi, Renzo Galanello, MD, Patrizio Bina, Maria D Cappellini, Antonio Piga, MD, Maria-Eliana Lai, Antonella Quarta, Gavino Casu, Silverio Perrotta, Khaled M Musallam, Gian Luca Forni, MD

Blood (2012) 120 (21): 3262.

https://doi.org/10.1182/blood.V120.21.3262.3262

Published: 2012

Journal Articles

Assessing the Efficacy of RBC Component Transfusion Therapy in Patients with Thalassemia Major

William F. Reed, MD, Claire Sherman, Filomena Longo, Marianna Genisio, Laurence Corash, MD, Renzo Galanello, MD, Antonio Piga, MD

Blood (2012) 120 (21): 1185.

https://doi.org/10.1182/blood.V120.21.1185.1185

Published: 2012

Journal Articles

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Amal El-Beshlawy, MD, Mohsen Elalfy, MD, Lee Lee Chan, MD, Yongrong Lai, MD, Kai-Hsin Lin, MD, Yesim Aydinok, MD, Renzo Galanello, MD, Ali El-Ali, MD, Nicolas Martin, MS, M Domenica Cappellini, MD

Blood (2012) 120 (21): 1028.

https://doi.org/10.1182/blood.V120.21.1028.1028

Published: 2012

Journal Articles

Assessment and Management of Iron Overload in β-Thalassemia Major Patients in Italy: A Real-Life Experience From the Webthal® Project

Antonio Piga, MD, Filomena Longo, Khaled M Musallam, Maria Domenica Cappellini, MD, Gian Luca Forni, MD, Giovanni Quarta, Francesco Chiavilli, Francesca Valeria Commendatore, Sergio Mulas, Vincenzo Caruso, Renzo Galanello, MD

Blood (2012) 120 (21): 1030.

https://doi.org/10.1182/blood.V120.21.1030.1030

Published: 2012

Journal Articles

Alfa Thalassemia Intermedia (HbH disease): How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Susanna Barella, MD, Ramon Simon-Lopez, MD, Nicola Di Gaetano, BS, PhD, Renzo Galanello, MD

Blood (2012) 120 (21): 5180.

https://doi.org/10.1182/blood.V120.21.5180.5180

Published: 2012

Journal Articles

Alfa Thalassemia Heterozygous: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Susanna Barella, MD, Ramon Simon-Lopez, MD, Nicola Di Gaetano, BS, PhD, Renzo Galanello, MD

Blood (2012) 120 (21): 5183.

https://doi.org/10.1182/blood.V120.21.5183.5183

Published: 2012

Journal Articles

Beta Thalassemia Trait: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Susanna Barella, MD, Ramon Simon-Lopez, MD, Nicola Di Gaetano, BS, PhD, Renzo Galanello, MD

Blood (2012) 120 (21): 5186.

https://doi.org/10.1182/blood.V120.21.5186.5186

Published: 2012

Journal Articles

Hereditary Spherocytosis: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Susanna Barella, MD, Ramon Simon-Lopez, MD, Nicola Di Gaetano, BS, PhD, Renzo Galanello, MD

Blood (2012) 120 (21): 5163.

https://doi.org/10.1182/blood.V120.21.5163.5163

Published: 2012

Journal Articles

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini

Blood (2012) 120 (5): 970–977.

https://doi.org/10.1182/blood-2012-02-412692

Published: 2012

Includes: Supplemental data

Journal Articles

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload

Ellis J. Neufeld, Renzo Galanello, Vip Viprakasit, Yesim Aydinok, Antonio Piga, Paul Harmatz, Gian Luca Forni, Farrukh T. Shah, Rachael F. Grace, John B. Porter, John C. Wood, Jennifer Peppe, Amber Jones, Hugh Young Rienhoff, Jr

Blood (2012) 119 (14): 3263–3268.

https://doi.org/10.1182/blood-2011-10-386268

Published: 2012

Includes: Supplemental data

Journal Articles

Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study

Ellis J. Neufeld, MD, PhD, Renzo Galanello, MD, Vip Viprakasit, MD; DPhil, Yesim Aydinok, MD, Antonio Piga, MD, Paul Harmatz, MD, Gian Luca Forni, MD, Farrukh T Shah, MBBS, MD, Rachael F. Grace, MD, John B. Porter, MD, Elliott Vichinsky, MD, John C Wood, MD, Ph.D, Jennifer Peppe, Amber Jones, Hugh Y Rienhoff, Jr., MD

Blood (2011) 118 (21): 690.

https://doi.org/10.1182/blood.V118.21.690.690

Published: 2011

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

Journal Articles

HPFH From Klf1 Haploinsufficiency Combined to Transcriptional Heterozygous β-Thalassemia

Paolo Moi, MD, Giuseppina M. Marini, PhD, Isadora Asunis, Loredana Porcu, PhD, Annalisa Cabriolu, PhD, Stefania Satta, Luciana Perseu, Liliana Maccioni, Antonio Cao, MD, Renzo Galanello, MD

Blood (2011) 118 (21): 2151.

https://doi.org/10.1182/blood.V118.21.2151.2151

Published: 2011

Journal Articles

KLF1 gene mutations cause borderline HbA 2

Lucia Perseu, Stefania Satta, Paolo Moi, Franca Rosa Demartis, Laura Manunza, Maria Carla Sollaino, Susanna Barella, Antonio Cao, Renzo Galanello

Blood (2011) 118 (16): 4454–4458.

https://doi.org/10.1182/blood-2011-04-345736

Published: 2011

Includes: Supplemental data

Journal Articles

Optimizing the Use of Deferasirox: Evidence of Synergy When Combined with Deferoxamine

Robert W Grady, PhD, Renzo Galanello, MD, Dorothy A Kleinert, NP, MPH, Carole S. Paley, MD, Patricia J. Giardina, MD

Blood (2010) 116 (21): 5163.

https://doi.org/10.1182/blood.V116.21.5163.5163

Published: 2010

Journal Articles

Homozygous deletion of the major alpha-globin regulatory element (MCS-R2) responsible for a severe case of hemoglobin H disease

Maria Carla Sollaino, Maria Elisabetta Paglietti, Daniela Loi, Rita Congiu, Rosanna Podda, Renzo Galanello

Blood (2010) 116 (12): 2193–2194.

https://doi.org/10.1182/blood-2010-04-281345

Published: 2010

Journal Articles

Amelioration of Sardinian β 0 thalassemia by genetic modifiers

Renzo Galanello, Serena Sanna, Lucia Perseu, Maria Carla Sollaino, Stefania Satta, Maria Eliana Lai, Susanna Barella, Manuela Uda, Gianluca Usala, Goncalo R. Abecasis, Antonio Cao

Blood (2009) 114 (18): 3935–3937.

https://doi.org/10.1182/blood-2009-04-217901

Published: 2009

Journal Articles

Genetic Modifiers of Homozygous Beta Zero Thalassemia.

Renzo Galanello, MD, Serena Sanna, Lucia Perseu, Maria Carla Sollaino, Stefania Satta, Manuela Uda, Gianluca Usala, Goncalo Abecasis, David Schlessinger, Antonio Cao, MD

Blood (2008) 112 (11): 1874.

https://doi.org/10.1182/blood.V112.11.1874.1874

Published: 2008

NARROW

International Comparison Study of Toxic Iron Assays in Patients with Iron Overload Disorders

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart Catheterization

Assessing the Efficacy of RBC Component Transfusion Therapy in Patients with Thalassemia Major

Deferasirox Treatment for up to 3 Years in Iron-Overloaded Pediatric Patients Reduces Serum Ferritin with a Manageable Safety Profile

Assessment and Management of Iron Overload in β-Thalassemia Major Patients in Italy: A Real-Life Experience From the Webthal® Project

Alfa Thalassemia Intermedia (HbH disease): How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Alfa Thalassemia Heterozygous: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Beta Thalassemia Trait: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Hereditary Spherocytosis: How the New Information Provided by the Routine Hematology Analysers May Help in Its Differential Diagnosis or Flagging

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload

Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

HPFH From Klf1 Haploinsufficiency Combined to Transcriptional Heterozygous β-Thalassemia

KLF1 gene mutations cause borderline HbA 2

Optimizing the Use of Deferasirox: Evidence of Synergy When Combined with Deferoxamine

Homozygous deletion of the major alpha-globin regulatory element (MCS-R2) responsible for a severe case of hemoglobin H disease

Amelioration of Sardinian β 0 thalassemia by genetic modifiers

Genetic Modifiers of Homozygous Beta Zero Thalassemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only